|Bid||164.18 x 1200|
|Ask||164.53 x 800|
|Day's Range||164.24 - 165.98|
|52 Week Range||133.65 - 179.92|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||24.73|
|Earnings Date||Oct 19, 2021|
|Forward Dividend & Yield||4.24 (2.59%)|
|Ex-Dividend Date||Aug 23, 2021|
|1y Target Est||188.88|
Yahoo Finance's Alexis Keenan provides the latest on how businesses are handling the COVID-19 vaccine mandate.
J&J vaccine data shows lasting durability and strong booster efficacy. However the company has yet to begin trials for a COVID-19 vaccine for children.
Johnson & Johnson became the latest COVID-19 vaccine maker to offer an update on booster doses Tuesday, when it said data from a Phase 3 trial and the real world found protection against hospitalization and death is greatly improved by a booster jab of its one-shot vaccine.